<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SULFISOXAZOLE <img border="0" src="../images/pr.gif"/></span><br/>(sul-fi-sox'a-zole)<br/><span class="topboxtradename">Gantrisin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">sulfonamide</span><br/><b>Pregnancy Category: </b>B (D if near term)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Short-acting derivative of sulfanilamide. Bacteriostatic action believed to be by competitive inhibition of <i>p</i>-aminobenzoic acid (PABA), thereby interfering with folic acid biosynthesis required for bacterial growth.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Exhibits broad antimicrobial spectrum against both gram-positive and gram-negative organisms.</p>
<h1><a name="uses">Uses</a></h1>
<p>Acute, recurrent, and chronic urinary tract infections and chancroid; adjunctive therapy in trachoma, chloroquine-resistant
         strains of malaria, acute otitis media due to <i>Haemophilus influenzae,</i> and meningococcal and <i>H. influenzae</i> meningitis. Ophthalmic preparations used in treatment of conjunctivitis, corneal ulcer, and other superficial eye infections
         and as adjunct to systemic sulfonamide therapy for trachoma. Topical vaginal preparation used for <i>H. vaginalis</i> vaginitis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity to sulfonamides, salicylates, or chemically related drugs; use in treatment of group A beta-hemolytic
         streptococcal infections; infants 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired kidney or liver function; severe allergy; bronchial asthma; blood dyscrasias; patients with G6PD deficiency.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Infection by Susceptible Organisms</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 24 g initially, followed by 48 g/d in 46 divided doses <span class="rdroute">Vaginal</span> 1 applicator full 12 times/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <i>&gt;2 mo,</i> 75 mg/kg initially, followed by 150 mg/kg/d in 46 divided doses (max: 6 g/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with full glass of water or other fluid; tablet may be crushed.</li>
<li>Store at 15°30° C (59°86° F) in tight, light-resistant containers.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, peripheral neuritis, peripheral neuropathy, tinnitus, hearing loss, vertigo, insomnia, drowsiness, mental depression,
      acute psychosis, ataxia, convulsions, kernicterus (newborns). <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting, diarrhea,</span> abdominal pains, hepatitis, jaundice, pancreatitis, stomatitis. <span class="typehead">Hematologic:</span> Acute hemolytic anemia (especially in patients with G6PD deficiency), <span class="speceff-life">aplastic anemia</span>, methemoglobinemia, <span class="speceff-life">agranulocytosis</span>, thrombocytopenia, leukopenia, eosinophilia, hypoprothrombinemia. <span class="typehead">Body as a Whole:</span> Headache, <span class="speceff-common">fever,</span> chills, arthralgia, malaise, allergic myocarditis, serum sickness, <span class="speceff-life">anaphylactoid reactions</span>, lymphadenopathy, local reaction following IM injection, fixed drug eruptions, diuresis, overgrowth of nonsusceptible organisms,
      LE phenomenon. <span class="typehead">Skin:</span> Pruritus, urticaria, rash, erythema multiforme including <span class="speceff-both">Stevens-Johnson syndrome exfoliative, dermatitis,</span> alopecia, photosensitivity, vascular lesions. <span class="typehead">Urogenital:</span> <span class="speceff-common">Crystalluria,</span> hematuria, proteinuria, anuria, toxic nephrosis, reduction in sperm count. <span class="typehead">Metabolic:</span> Goiter, hypoglycemia. <span class="typehead">Special Senses:</span> Conjunctivitis, conjunctival or scleral infection, retardation of corneal healing (ophthalmic ointment). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Sulfonamides may interfere with <span class="alt">BSP</span> retention and <span class="alt">PSP</span> excretion tests and may affect results of <span class="alt">thyroid function</span> tests (<span class="alt">I-131</span> may be decreased for about 7 d). Large doses of sulfonamides reportedly may produce false-positive <span class="alt">urine glucose</span> determinations with <span class="alt">copper reduction methods</span> (e.g., <span class="alt">Benedict's</span> and <span class="alt">Clinitest</span>). <small>SULFONAMIDES</small> may produce false-positive results for <span class="alt">urinary protein</span> (with <span class="alt">sulfosalicylic acid test</span>) and may interfere with <span class="alt">urine urobilinogen</span> determinations using <span class="alt">Ehrlich's reagent</span> or <span class="alt">Urobilistix.</span> Follow-up cultures are unreliable unless PABA is added to culture medium.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">paba-containing local anesthetics</span> may antagonize sulfa's effects; <span class="classification">oral anticoagulants</span> potentiate hypoprothrombinemia; may potentiate <span class="classification">sulfonylurea</span>-induced hypoglycemia; may decrease concentrations of <b>cyclosporine;</b> may increase levels of <b>phenytoin</b>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 24 h. <span class="typehead">Distribution:</span> Distributed in extracellular space; crosses bloodbrain barrier and placenta; detected in breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 95% excreted in urine in 24 h. <span class="typehead">Half-Life:</span> 4.67.8 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain a specimen for C&amp;S prior to initiation of therapy. Perform frequent kidney function tests and urinalyses;
            complete blood counts and liver function tests, especially during regimens longer than 2 wk.
         </li>
<li>Monitor I&amp;O. Report oliguria and changes in I&amp;O ratio. Fluid intake should be adequate to support urinary output of at least
            1500 mL/d to prevent crystalluria and stone formation.
         </li>
<li>Check urine pH daily with Nitrazine paper or Labstix; fall in urinary pH (more acidic) increases risk of crystalluria.</li>
<li>Report increasing urine acidity. If urine is highly acidic, physician may prescribe a urinary alkalinizer.</li>
<li>Monitor temperature. Sudden appearance of fever may signify sensitization (serum sickness) or hemolytic anemia (frequent in
            patients with G6PD deficiency, which is most common among black males and Mediterranean ethnic groups). Reactions generally
            develop within 10 d. Agranulocytosis may develop after 10 d6 wk of therapy.
         </li>
<li>Report early manifestations of blood dyscrasias or hypersensitivity reactions immediately (fever with sore throat, malaise,
            unusual fatigue, joint pains, pallor, bleeding tendencies, rash, jaundice).
         </li>
<li>Be alert for skin lesions, papular or vesiculobullous lesions, especially on sun-exposed areas, Stevens-Johnson syndrome (severe
            erythema multiforme) may be preceded by high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urticaria, balanitis
            (inflammation of penis or clitoris). Termination of drug therapy is indicated.
         </li>
<li>Observe diabetic patients receiving oral hypoglycemic agents closely for hypoglycemic reactions. Obtain blood glucose and
            HbA1c levels before and shortly after initiation of therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not take OTC medications without consulting physician. Many analgesic mixtures contain aspirin in combination with <i>p</i>-aminobenzoic acid; avoid to prevent crystallization in urine.
         </li>
<li>Use or add barrier contraceptives if using hormonal contraceptives, which may be unreliable while taking this drug.</li>
<li>Avoid exposure to ultraviolet light and excessive sunlight to prevent photosensitivity reaction during therapy and for several
            months after treatment is discontinued.
         </li>
<li>Inform dentist or new physician that you are taking a sulfonamide.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>